GW Pharmaceuticals PLC closed the most recent trading day at $168.14, moving -0.26% from the previous trading session. This change lagged the S&P 500's 1.16% gain on the day. Elsewhere, the Dow gained 1.27%, while the tech-heavy Nasdaq added 1.29%.
Heading into today, shares of the company had lost 2% over the past month, lagging the Medical sector's gain of 1.35% and the S&P 500's gain of 1.92% in that time.
Wall Street will be looking for positivity from GWPH as it approaches its next earnings report date. In that report, analysts expect GWPH to post earnings of -$2.42 per share. This would mark year-over-year growth of 22.44%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $23.19 million, up 592.18% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$7.98 per share and revenue of $132.12 million. These totals would mark changes of +24.43% and +679.18%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for GWPH. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 16.09% higher. GWPH is holding a Zacks Rank of #2 (Buy) right now.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 81, putting it in the top 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow GWPH in the coming trading sessions, be sure to utilize Zacks.com.
Image: Bigstock
GW Pharmaceuticals PLC (GWPH) Stock Sinks As Market Gains: What You Should Know
GW Pharmaceuticals PLC closed the most recent trading day at $168.14, moving -0.26% from the previous trading session. This change lagged the S&P 500's 1.16% gain on the day. Elsewhere, the Dow gained 1.27%, while the tech-heavy Nasdaq added 1.29%.
Heading into today, shares of the company had lost 2% over the past month, lagging the Medical sector's gain of 1.35% and the S&P 500's gain of 1.92% in that time.
Wall Street will be looking for positivity from GWPH as it approaches its next earnings report date. In that report, analysts expect GWPH to post earnings of -$2.42 per share. This would mark year-over-year growth of 22.44%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $23.19 million, up 592.18% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$7.98 per share and revenue of $132.12 million. These totals would mark changes of +24.43% and +679.18%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for GWPH. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 16.09% higher. GWPH is holding a Zacks Rank of #2 (Buy) right now.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 81, putting it in the top 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow GWPH in the coming trading sessions, be sure to utilize Zacks.com.